临床肝胆病杂志
臨床肝膽病雜誌
림상간담병잡지
CHINESE JOURNAL OF CLINICAL HEPATOLOGY
2015年
1期
99-102
,共4页
肝肿瘤%化学栓塞,治疗性%冷冻外科手术
肝腫瘤%化學栓塞,治療性%冷凍外科手術
간종류%화학전새,치료성%냉동외과수술
liver neoplasms%chemoembolization,therapeutic%cryosurgery
目的：观察肝动脉化疗栓塞术（TACE）联合氩氦刀冷冻消融技术治疗不能手术的中晚期肝癌患者的有效性和安全性。方法对2008年5月－2010年6月郑州大学附属洛阳中心医院收治的35例肝癌患者首先行TACE治疗2～3周，然后行氩氦刀冷冻消融治疗，1～2周后再次进行TACE治疗，治疗结束后评价近期疗效，并随访生存情况。两组间数据比较采用t检验，生存曲线采用Kaplan－Meier法进行生存分析。结果35例患者均可评价疗效，其中完全缓解7例，部分缓解21例，稳定4例，进展3例；临床治疗有效率为80．00％，疾病控制率为91．43％；2、3年生存率分别为45．6％、39．4％。35例患者治疗前甲胎蛋白（AFP）为（837．6±216．7）μg／L，治疗后AFP为（206．2±48．6）μg ／L，差异有统计学意义（t＝2．673，P＜0．05）。结论 TACE联合氩氦刀冷冻消融是治疗不能手术的中晚期肝癌患者的可靠方法，具有创伤小、恢复快、并发症少等特点。
目的：觀察肝動脈化療栓塞術（TACE）聯閤氬氦刀冷凍消融技術治療不能手術的中晚期肝癌患者的有效性和安全性。方法對2008年5月－2010年6月鄭州大學附屬洛暘中心醫院收治的35例肝癌患者首先行TACE治療2～3週，然後行氬氦刀冷凍消融治療，1～2週後再次進行TACE治療，治療結束後評價近期療效，併隨訪生存情況。兩組間數據比較採用t檢驗，生存麯線採用Kaplan－Meier法進行生存分析。結果35例患者均可評價療效，其中完全緩解7例，部分緩解21例，穩定4例，進展3例；臨床治療有效率為80．00％，疾病控製率為91．43％；2、3年生存率分彆為45．6％、39．4％。35例患者治療前甲胎蛋白（AFP）為（837．6±216．7）μg／L，治療後AFP為（206．2±48．6）μg ／L，差異有統計學意義（t＝2．673，P＜0．05）。結論 TACE聯閤氬氦刀冷凍消融是治療不能手術的中晚期肝癌患者的可靠方法，具有創傷小、恢複快、併髮癥少等特點。
목적：관찰간동맥화료전새술（TACE）연합아양도냉동소융기술치료불능수술적중만기간암환자적유효성화안전성。방법대2008년5월－2010년6월정주대학부속락양중심의원수치적35례간암환자수선행TACE치료2～3주，연후행아양도냉동소융치료，1～2주후재차진행TACE치료，치료결속후평개근기료효，병수방생존정황。량조간수거비교채용t검험，생존곡선채용Kaplan－Meier법진행생존분석。결과35례환자균가평개료효，기중완전완해7례，부분완해21례，은정4례，진전3례；림상치료유효솔위80．00％，질병공제솔위91．43％；2、3년생존솔분별위45．6％、39．4％。35례환자치료전갑태단백（AFP）위（837．6±216．7）μg／L，치료후AFP위（206．2±48．6）μg ／L，차이유통계학의의（t＝2．673，P＜0．05）。결론 TACE연합아양도냉동소융시치료불능수술적중만기간암환자적가고방법，구유창상소、회복쾌、병발증소등특점。
Objective To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE)combined with argon-heli-um cryoablation in patients with advanced unresectable primary hepatocellular carcinoma (HCC).Methods TACE was performed in 35 patients with primary HCC who were admitted to our hospital from May 2008 to June 2010.After 2-3 weeks of treatment,the patients re-ceived argon-helium cryoablation,followed by a second TACE in 1 -2 weeks.The short-term efficacy after treatment was evaluated and the long-term survival was studied by follow-up.Comparison between two groups was made by t test,and survival was analyzed using the Kaplan-Meier survival curves.Results The clinical outcomes of all 35 patients were evaluated.Complete response was observed in 7 pa-tients,partial response in 21 patients,stable disease in 4 patients,and progressive disease in 3 patients.The overall response rate was 80. 00%,and the disease control rate was 91.43%.The 2-and 3-year survival rates were 45.6% and 39.4%,respectively.The level of alpha-fetoprotein AFP in patients after the treatment (206.2 ±48.6 μg/L)was significantly lower than that before the treatment (837.6 ± 216.7 μg/L)(t=2.673,P<0.05).Conclusion TACE combined with argon-helium cryoablation is a reliable therapeutic approach in treating advanced unresectable primary HCC,and the advantages include minimal invasion,fast recovery,and few complications.
